-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to statistics, last week (4 Yue 5 Ri Zhi 4 Yue 9 Ri ) a total of 114 listed companies received from fund companies, securities companies, and other institutions of private sun 121 times research.
According to statistics, last week (4 Yue 5 Ri Zhi 4 Yue 9 Ri ) a total of 114 listed companies received from fund companies, securities companies, and other institutions of private sun 121 times research.
From an industry perspective, last week’s institutional surveys focused on industries such as electronics, medicine, chemicals, automobile manufacturing, software and information technology services.
From the perspective of specific companies, among the top 15 listed companies in the number of institutional surveys , Xinyangfeng, FAW Jiefang, Levima, and Shanghai Pharmaceutical have all obtained more than 40 institutional surveys .
Xinyangfeng, a leading domestic compound fertilizer company, received 82 surveys last week .
FAW Jiefang, which has been surveyed by 62 institutions, said that the domestic medium and heavy truck market demand has been strong in recent years.
Levima Technologies, a domestic EVA photovoltaic film material manufacturer, has received 49 surveys.
Shanghai Pharmaceuticals has obtained surveys from 44 institutions, and the company expects that the proportion of medical insurance expenditures and innovative drugs in the overall medical insurance expenditures will increase in the future.
At present, the company has initially completed the restructuring of the R&D system, and 25 innovative drugs are in the R&D pipeline.